Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Two Tepotinib Formulations in Healthy Volunteers
NCT03021642Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tepotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time at 504 hours, Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity at 504 hours and 2 more. Started Jan 2016; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03021642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03021642.